Interestingly, NX-1607 is also tested in diffuse large B cell lymphoma (DLBCL, post-Richter transformation), which is supported by preclinical data showing increased rituximab antibody-dependent cellular cytotoxicity-driven efficacy by CBL-B inhibition (48). Here, CBLB is linked to diffuse large B-cell lymphoma.